A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
Latest Information Update: 10 Mar 2026
At a glance
- Drugs Guselkumab (Primary) ; Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms G-LINK
- Sponsors Janssen-Cilag
Most Recent Events
- 10 Mar 2026 New trial record